Amy Quinlan - 08 May 2026 Form 3 Insider Report for Voyager Therapeutics, Inc. (VYGR)

Reporting relationship: Principal Accounting Officer
Issuer ticker: VYGR
Reported as of: 08 May 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 May 2026, 16:01:14 UTC
Prior SEC filing: 08 Nov 2024
Source filing: View source filing
Reporting owner signature: /s/ Gregory L. Shiferman, as Attorney-in-Fact for Amy Quinlan

Key filing fact

Amy Quinlan filed Form 3 for Voyager Therapeutics, Inc. (VYGR) on 18 May 2026.

Key facts

This page summarizes Amy Quinlan's Form 3 filing for Voyager Therapeutics, Inc. (VYGR).
0 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 18 May 2026, 16:01.

Change

Previous filing in this sequence was filed on 08 Nov 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002027706 Primary reporting owner

Quinlan Amy

Relationship: Principal Accounting Officer
Address: C/O VOYAGER THERAPEUTICS, INC.,, 75 HAYDEN AVENUE, LEXINGTON
Signature: /s/ Gregory L. Shiferman, as Attorney-in-Fact for Amy Quinlan
Signature date: 18 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYGR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 36,749
Date: 08 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VYGR holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 08 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $5.28
Footnotes: F2

VYGR holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 08 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,500
Exercise price: $3.68
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Includes shares of common stock issuable under restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "2015 Plan") and the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan") that vest periodically. Each RSU represents the right to receive one share of common stock upon vesting.

Footnote F2

This stock option was issued pursuant to the 2015 Plan. The vesting commencement date of the option is the grant date, January 13, 2025. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting on the one-year anniversary of the vesting commencement date, and an additional 1/36th of the shares of common stock underlying the option vesting monthly thereafter, subject to the Reporting Person's continued service.

Footnote F3

This stock option was issued pursuant to the 2025 Plan. The vesting commencement date of the option is the grant date, February 06, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting on the first month anniversary of the vesting commencement date, and an additional 1/48th of shares underlying the option vesting monthly thereafter, subject to the Reporting Person's continued service.

SEC remarks

Exhibit 24.1: Limited Power of Attorney